Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients

CAMBRIDGE, Mass. -  Biogen (Nasdaq: BIIB) today announced new results from the NURTURE study, adding data to the longest study ofspinal muscular atrophy(SMA) in pre-symptomatic infants (n=25). These data reported, after ...

Sangamo Therapeutics Announces Nature Medicine Publication Detailing the Activity of Disease Allele-Selective Zinc Finger Proteins in Preclinical Models of Huntington’s Disease

BRISBANE, Calif. -Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the publication of a manuscript describing the activity of allele-selective zinc finger protein transcription-facto...

Foundation Medicine Expands Indication for FoundationOne®CDx as a Companion Diagnostic for LYNPARZA® (Olaparib)

CAMBRIDGE, Mass. - Foundation Medicine, Inc. today announced it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic for LYNPARZA® (Olaparib) f...

Boston Biomedical, Inc. Announces Update on Phase 3 CanStem111P Study of Napabucasin in Patients with Metastatic Pancreatic Cancer Following Interim Analysis

CAMBRIDGE, Mass. - Boston Biomedical, Inc. today announced that the CanStem111P study evaluating the safety and efficacy of investigational agent napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-...

Biohaven Enrolls First Patient in Phase 2 Clinical Trial of Rimegepant, Oral CGRP Receptor Antagonist, for Treatment Refractory Trigeminal Neuralgia

NEW HAVEN, Conn. - Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsych...

Dicerna™ to Begin Clinical Development of DCR-A1AT for Treatment of Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

CAMBRIDGE -  DicernaTMPharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of ribonucleic acid interference (RNAi) therapies, today announced it submitted a Clinical Trial Authorization ...

Laboratory Testing of Known Compounds for Cancer Treatment Efficacy

AUSTIN, Texas - Sodium dichloroacetate (DCA) has been investigated as a novel cancer therapy since 2007 when Bonnet et al published research study demonstrating the efficacy of DCA in treating human cancers by inhibition...

World’s leading infectious cause of blindness shows huge decline

Cape Town – The number of people at risk oftrachoma, the world’s leading infectious cause of blindness, has fallen from 1.5 billion in 2002 to just over 142 million this year, according to the World Health Organisation (...

Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease

NEW YORK and CLEVELAND - Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its A...

Alnylam Announces Approval in Japan of ONPATTRO for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy

CAMBRIDGE, Mass. & TOKYO -Alnylam Pharmaceuticals, Inc.(Nasdaq: ALNY), the leading RNAi therapeutics company, announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved ONPATTRO®(patisiran...